Beta-glucuronidase is an enzyme that breaks the tight bond between glucuronic acid and toxins in the intestines. The binding of toxins in the gut is protective by way of blocking their absorption and facilitating excretion. Higher levels of beta-glucuronidase may be associated with an imbalanced intestinal microbiota profile, as well as higher circulating estrogens and lower fecal excretion of estrogens in premenopausal women.
Learn more »
4 to 6 days
Click any analyte name for additional clinical information, including reference ranges, specimen collection, stability and rejection criteria.
List price applies when filing with insurance or Medicare, or when billing a patient directly.
Prompt payment pricing applies when billing to a physician account or prepayment is received with the test.
Doctor's Data offers profiles containing multiple analytes. *Multiple analytes may be billed under a single CPT code. Many analytes can be ordered individually. Pricing may vary. Click on a specific analyte for more information or read our detailed billing and payment policies.
The CPT codes listed on our website are for informational purposes only. This information is our interpretation of CPT coding requirements and may not necessarily be correct. You are advised to consult the CPT Coding Manual published by the American Medical Association. Doctor's Data, Inc. takes no responsibility for billing errors due to your use of any CPT information from our website.
β-glucuronidase (β-G) is an enzyme that breaks the tight bond between glucuronic acid and toxins in the intestines. The liver and intestine bind toxins, steroid hormones and some dietary components to glucuronic acid. That is a protective process that limits absorption and enterohepatic resorption of toxins, and enhances excretion. A high level of activity of β-G in the gut is not desirable. A low level of β-G activity is not known to be of any direct clinical consequence.
β -glucuronidase is produced by the intestinal epithelium and certain intestinal bacteria. Observational studies have indicated a correlation between high β-G activity and certain cancers, but a definitive causal relationship has not been established. Higher levels of β-G have been associated with higher circulating estrogens and lower fecal excretion of estrogens in premenopausal women. A potential dietary carcinogen derived from cooked meat and fish induces high β-G activity and prolongs internal exposure to the toxin in an experimental animal model.
Diet and intestinal bacterial imbalance modulate β-G activity. High fat, high protein and low fiber diets are associated with higher β-G activity compared to vegetarian or high soluble fiber diets. Higher β-G may be associated with an imbalanced intestinal microbiota profile. Some major bacterial producers of fecal β-G include Bifidobacterium, Lactobacillus, Escherichia coli, Clostridium, Bacteroides fragilis and other Bacteroides species, Ruminococcus gnavus, and species that belong to the genera Staphylococcus and Eubacterium.
Low β-G activity is an indicator of abnormal metabolic activity among the intestinal microbiota that may be influenced by dietary extremes, diminished abundance and diversity of the intestinal microbiota, or heavy probiotic and/or prebiotic supplementation. A low fat, low meat and high fiber diet, such as consumed by strict vegetarians, may be associated with lower β-G activity compared to a typical “Western diet.” High-end consumption of soluble fiber (e.g. inulin) and supplementation with Lactobacillus acidophilus may be inconsequentially associated with lower fecal β-G.